Patents by Inventor Anthony William James Cooper

Anthony William James Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS
    Publication number: 20220089590
    Abstract: The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Application
    Filed: June 17, 2021
    Publication date: March 24, 2022
    Inventors: Anthony William James Cooper, Nicole Cathleen Goodwin, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, Jeffrey K. Kerns, Hendrika Maria Gerarda Willems, Hongxing Yan
  • Bisaryl amides as NRF2 activators
    Patent number: 11078216
    Abstract: The present invention relates to bisaryl amide analogs, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: August 3, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: James Francis Callahan, Vincent J. Colandrea, Anthony William James Cooper, Nicole Cathleen Goodwin, Chelsea Ariane Huff, Joel Karpiak, Jeffrey K. Kerns, Hong Nie
  • Ether linked triazoles as NRF2 activators
    Patent number: 11059816
    Abstract: The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: July 13, 2021
    Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, ASTEX THERAPEUTICS LIMITED
    Inventors: Anthony William James Cooper, Nicole Cathleen Goodwin, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, Jeffrey K. Kerns, Hendrika Maria Gerarda Willems, Hongxing Yan
  • Pyridinone dicarboxamide for use as bromodomain inhibitors
    Patent number: 10927080
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: February 23, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Stephen John Atkinson, Helen Elizabeth Aylott, Anthony William James Cooper, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Chemical compounds
    Patent number: 10793559
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: October 6, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Nicholas Paul Barton, Sebastien Andre Campos, Edward Paul Cannons, Anthony William James Cooper, Kenneth David Down, Kevin James Doyle, Julie Nicole Hamblin, Graham George Adam Inglis, Armelle Le Gall, Vipulkumar Kantibhai Patel, Simon Peace, Andrew Sharpe, Gemma Victoria White
  • ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS
    Publication number: 20200071317
    Abstract: The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Application
    Filed: December 11, 2017
    Publication date: March 5, 2020
    Inventors: Anthony William James COOPER, Nicole Cathleen GOODWIN, Charlotte Mary GRIFFITHS-JONES, Thomas Daniel HEIGHTMAN, Jeffrey K. KERNS, Hendrika Maria Gerarda WILLEMS, Hongxing YAN
  • CHEMICAL COMPOUNDS
    Publication number: 20200071311
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: September 17, 2019
    Publication date: March 5, 2020
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew ANDERSON, Nicholas Paul BARTON, Sebastien Andre CAMPOS, Edward Paul CANNONS, Anthony William James COOPER, Kenneth David DOWN, Kevin James DOYLE, Julie Nicole HAMBLIN, Graham George Adam INGLIS, Armelle LE GALL, Vipulkumar Kantibhai PATEL, Simon PEACE, Andrew SHARPE, Gemma Victoria WHITE
  • PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20190359572
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Application
    Filed: August 8, 2019
    Publication date: November 28, 2019
    Inventors: Stephen John ATKINSON, Helen Elizabeth AYLOTT, Anthony William James COOPER, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Thomas George Christopher HAYHOW, Matthew J. LINDON, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • BISARYL AMIDES AS NRF2 ACTIVATORS
    Publication number: 20190330238
    Abstract: The present invention relates to bisaryl amide analogs, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Application
    Filed: December 11, 2017
    Publication date: October 31, 2019
    Inventors: James Francis CALLAHAN, Vincent J. COLANDREA, Anthony William James COOPER, Nicole Cathleen GOODWIN, Chelsea Ariane HUFF, Joel KARPIAK, Jeffrey K. KERNS, Hong NIE
  • Chemical compounds
    Patent number: 10457674
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: October 29, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Nicholas Paul Barton, Sebastien Andre Campos, Edward Paul Cannons, Anthony William James Cooper, Kenneth David Down, Kevin James Doyle, Julie Nicole Hamblin, Graham George Adam Inglis, Armelle Le Gall, Vipulkumar Kantibhai Patel, Simon Peace, Andrew Sharpe, Gemma Victoria White
  • Pyridinone dicarboxamide for use as bromodomain inhibitors
    Patent number: 10428026
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: October 1, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Stephen John Atkinson, Helen Elizabeth Aylott, Anthony William James Cooper, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • CHEMICAL COMPOUNDS
    Publication number: 20190040051
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: February 10, 2017
    Publication date: February 7, 2019
    Inventors: Niall Andrew ANDERSON, Nicholas Paul BARTON, Sebastien Andre CAMPOS, Edward Paul CANNONS, Anthony William James COOPER, Kenneth David DOWN, Kevin James DOYLE, Julie Nicole HAMBLIN, Graham George Adam INGLIS, Armelle LE GALL, Vipulkumar Kantibhai PATEL, Simon PEACE, Andrew SHARPE, Gemma Victoria WHITE
  • PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20180258044
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Application
    Filed: August 31, 2016
    Publication date: September 13, 2018
    Inventors: Stephen John ATKINSON, Helen Elizabeth AYLOTT, Anthony William James COOPER, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Thomas George Christopher HAYHOW, Matthew J. LINDON, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • Pyrazole compounds acting against allergic, immune and inflammatory conditions
    Patent number: 9156791
    Abstract: The present invention relates to a pyrazole amide derivative, pharmaceutical compositions containing this compound and to its use in therapy.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: October 13, 2015
    Assignee: Glaxo Group Limited
    Inventors: Anthony William James Cooper, Paul Martin Gore, David House
  • Pyrazole compounds acting against allergic, inflammatory and immune disorders
    Patent number: 9149462
    Abstract: The present invention relates to pyrazole amide derivatives pharmaceutical compositions containing these compounds and to their use in therapy.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: October 6, 2015
    Assignee: Glaxo Group Limited
    Inventors: Anthony William James Cooper, Paul Martin Gore, David House
  • PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS
    Publication number: 20130217658
    Abstract: The present invention relates to pyrazole amide derivatives pharmaceutical compositions containing these compounds and to their use in therapy.
    Type: Application
    Filed: October 19, 2011
    Publication date: August 22, 2013
    Applicant: GLAXO GROUP LIMITED
    Inventors: Anthony William James Cooper, Paul Martin Gore, David House
  • Pyrazole Compounds Acting Against Allergic, Immune and Inflammatory Conditions
    Publication number: 20130203705
    Abstract: The present invention relates to a pyrazole amide derivative, pharmaceutical compositions containing this compound and to its use in therapy.
    Type: Application
    Filed: October 19, 2011
    Publication date: August 8, 2013
    Applicant: Glaxo Group Limited
    Inventors: Anthony William James Cooper, Paul Martin Gore, David House
  • N-pyrazolyl carboxamides as CRAC channel inhibitors
    Patent number: 8399436
    Abstract: The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: March 19, 2013
    Assignee: Glaxo Group Limited
    Inventors: David George Allen, Diane Mary Coe, Anthony William James Cooper, Paul Martin Gore, David House, Stefan Senger, Steven Leslie Sollis, Sadie Vile, Caroline Wilson
  • 7,8-dihydropyrido[2,3-d]pyrimidin-4-yl substituted compounds as inhibitors of p38 kinase
    Patent number: 8354416
    Abstract: Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: January 15, 2013
    Assignee: Glaxo Group Limited
    Inventors: James F. Callahan, Jeffrey C. Boehm, Anthony William James Cooper, Stefano Livia, Paul Bamborough, Neysa Nevins, Zehong Wan, Beth A. Norton, Xichen Lin
  • Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions
    Publication number: 20120277279
    Abstract: The present invention provides compounds of formula (I): a process for their preparation, to pharmaceutical compositions comprising the compounds and the preparation of said compositions, to intermediates and to use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation, allergy and/or auto-immune conditions.
    Type: Application
    Filed: July 13, 2012
    Publication date: November 1, 2012
    Inventors: Heather Anne BARNETT, Ian Baxter Campbell, Diane Mary Coe, Anthony William James Cooper, Graham George Adam Inglis, Haydn Terence Jones, Steven Philip Keeling, Simon John Fawcett MacDonald, Iain McFarlane McLay, Philip Alan Skone, Gordon Gad Weingarten, James Michael Woolven